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Abstract
Background: Cutaneous squamous cell carcinomas (cSCC) are the primary cause of premature deaths in patients
suffering from the rare skin-fragility disorder recessive dystrophic epidermolysis bullosa (RDEB), which is in marked
contrast to the rarely metastasizing nature of these carcinomas in the general population. This remarkable
difference is attributed to the frequent development of chronic wounds caused by impaired skin integrity.
However, the specific molecular and cellular changes to malignancy, and whether there are common players in
different types of aggressive cSCCs, remain relatively undefined.
Methods: MiRNA expression profiling was performed across various cell types isolated from skin and cSCCs.
Microarray results were confirmed by qPCR and by an optimized in situ hybridization protocol. Functional impact of
overexpression or knock-out of a dysregulated miRNA was assessed in migration and 3D-spheroid assays. Sample-
matched transcriptome data was generated to support the identification of disease relevant miRNA targets.
Results: Several miRNAs were identified as dysregulated in cSCCs compared to control skin. These included the
metastasis-linked miR-10b, which was significantly upregulated in primary cell cultures and in archival biopsies. At
the functional level, overexpression of miR-10b conferred the stem cell-characteristic of 3D-spheroid formation
capacity to keratinocytes. Analysis of miR-10b downstream effects identified a novel putative target of miR-10b, the
actin- and tubulin cytoskeleton-associated protein DIAPH2.
Conclusion: The discovery that miR-10b mediates an aspect of cancer stemness – that of enhanced tumor cell
adhesion, known to facilitate metastatic colonization – provides an important avenue for future development of
novel therapies targeting this metastasis-linked miRNA.
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Background
While the incidence of cutaneous squamous cell carcin-
omas (cSCC) in Western industrialized societies has in-
creased in recent years, it has remained relatively easy to
treat, especially at early stages of the disease [1]. However,
in some cases cSCCs metastasize, worsening the prognosis
of patients. A special case of cSCCs occurs in patients
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suffering from the rare genodermatosis recessive-
dystrophic epidermolysis bullosa (RDEB). These patients
are at high risk of developing a particularly aggressive type
of cSCC with a high metastatic potential that is linked to
changes in the extracellular matrix (ECM), caused by loss-
of-function mutations in the COL7A1 gene [2]. A lack of
functional type-VII collagen (C7) at the dermal-epidermal
junction (DEJ) sensitizes skin to blistering and erosions,
upon minor physical stress or trauma [3]. Patients with
RDEB present with congenital generalized blistering and a
number of severe secondary manifestations. cSCCs arise in
nearly all RDEB patients by the age of 45, and associated
metastatic disease is the primary cause of premature deaths
[4]. Several mechanisms are thought to contribute to the
aggressive and rapidly progressing nature of RDEB-cSCCs.
In general, the skin’s constant need to repair itself,
coupled with the stalled inflammatory processes, and ab-
errant TGF-ß signaling associated with microbial chal-
lenge [5–9], are considered major risk factors. To which
extent these inflammatory changes are linked to the par-
ticularly aggressive form of cSCC associated with RDEB,
and if these tumors have characteristics in common with
cSCCs that present with an aggressive behaviour in other-
wise healthy people, remains unknown.
We focused on post-transcriptional regulatory pro-
cesses in aggressive cSCCs, in particular on micro-RNAs
(miRNAs). MiRNAs are short (20–25 nucleotide) RNA
molecules, which are key regulators of normal cell func-
tions. In a healthy system, miRNAs are predicted to me-
diate the post-transcriptional control of up to 60% of all
expressed genes [10]. Their dysregulation is associated
with several pathologic states, including cancer, heart
disease, and obesity, and they are attributed a promising
potential for therapeutic developments [11, 12]. In recent
years, both, oncogenic miRNAs (onco-miRs) and tumor sup-
pressive miRNAs, have been identified as playing important
roles in cancer progression. In addition, a class of miRNAs
have been shown to have specific pro-metastatic properties.
A key metasta-miR, miR-10b, has been associated with
tumor promoting properties, as well as the growth of
metastatic foci in breast cancer in various landmark studies
[13–15]. MiR-10b is encoded by a highly conserved genomic
region, which is located near the homeobox D (HOXD) clus-
ter on chromosome 2 [16]. It has been linked to a range of
functions, including regulation of angiogenesis and promo-
tion of cell invasion [17–20]. Increased serum levels of miR-
10b are associated with poor prognosis in melanoma and
breast cancer [21, 22], and intravenous injections of miR-10b
inhibitors in tumor-bearing mice dramatically reduced breast
cancer cell metastasis [13, 15, 23]. In addition, a meta-
analysis of miR-10b levels and clinical outcomes in various
cancers, demonstrated that overexpression was associated
with poor overall survival, indicating that miR-10b might be
a promising prognostic biomarker [24].
In this study, we substantially add to our understand-
ing of the role of miR-10b, by reporting for the first time
on the dysregulation of this miRNA in aggressive cSCC.
Both, RDEB- and otherwise healthy donor-related cSCCs
(HC-cSCCs) were classified and included in the study
according to their potential to metastasize. We show
that miR-10b expression is linked to a cancer stem cell-
like phenotype in a 3D organotypic model. Taken as a
whole, this work provides a new explanation of malig-
ancy in cSCCs, and a novel target for further develop-
ment of markers and therapies to treat cSCCs.
Methods
Patient samples and cell lines
For this study, primary cells were used for microarray experi-
ments, as well as for validations. For miR-10b overexpres-
sion, we used HPV16 E6/E7 immortalized keratinocytes. All
cells were cultured in defined, serum-free CnT-Prime Epi-
thelial Culture Medium (CELLnTEC, Cat No. CnT-PR) at
37 °C / 5% CO2 in a humidified incubator. For more detailed
information regarding origin of the cell lines and donor de-
scription see Supplementary Information and Supplementary
Table S1 in Additional File 1.
Microarrays
For total RNA and miRNA isolation from cell cultures, we
used miRNeasy Mini Kit (Qiagen, 217004), according to
manufacturer’s protocol. For transcriptome analysis, an
Affymetrix Clariom™D (Thermo Fisher, 902922) was ap-
plied and an Affymetrix GeneChip™ miRNA 4.1 platform
was used for miRNA analysis (Thermo Fisher, 902409).
Arrays were performed by the service provider “Core Fa-
cility Genomics at the Medical University Vienna” in ac-
cordance with manufacturer’s instructions. RNA quality
was confirmed on a Bioanalyzer prior to hybridization
onto a respective array. Quality assessment of microarray
data was conducted via “Transcriptome Analysis Console”
(Applied Biosystems v4.0.0.25).
Bioinformatic data processing and statistical analysis
All data processing and analysis was documented and
performed in statistical software R (v3.5.1). Scripts are
available upon request. For detailed statistical analysis
refer to Supplementary Information in Additional File 1.
For statistical analysis Student’s t-test was performed
using the GraphPad Prism (v 5.03) or Excel software,
and error bars represent standard error of mean (SEM),
unless mentioned otherwise. Details regarding number
of replicates can be found in figure legends.
TaqMan qPCR miRNA assays
For primary (pri)-miRNA assays cDNA was synthesized
from 1 μg total RNA. For reverse transcription, the High
Capacity RNA-to-cDNA kit (Applied Biosystems,
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4387406) was used according to the manufacturer’s proto-
col. TaqMan pri-miRNA assays (Thermo Fisher Scientific,
4427012, Hs03302884_pri) including the TaqMan Gene
Expression Master Mix, were used. RNaseP (Thermo
Fisher Scientific, 4401631) served as endogenous control.
For mature miRNA validations we used TaqMan Ad-
vanced miRNA assays (Thermo Fisher Scientific, A25576),
2x Fast Advanced Master Mix, and respectively diluted
miRNA templates. miR-320a-3p (Thermo Fisher Scientific,
478594_mir) was used as endogenous control. All reactions
were performed in technical triplicates, and repeated as inde-
pendently performed experiments for at least three times.
Fluorescence-based in situ hybridization of miR-10b on
cultured cells and formalin-fixed paraffin embedded
(FFPE) tissue sections
An optimized in situ hybridization protocol was applied,
based on the method described by Gasch et al. [13] and
the manufacturer’s recommendations (Qiagen, 339450).
In brief, 8 μm FFPE tissue sections were deparaffinized
in xylene, washed and rehydrated in serial dilution of
ethanol / dH2O. Antigen retrieval was performed in cit-
rate buffer pH 6.0 at 100 °C.
Cells were cultured in 8-well glass chamber slides (Milli-
cell EZ Slide, PEZGS0816) and fixed with 4% PFA in PBS
at room temperature, and permeabilized by incubation in
1% Triton-X100 in PBS. After re-fixation in 4% PFA in
PBS, cells were washed twice in PBS and incubated for 20
min at 54 °C (60min at 52 °C for tissue sections) in miR-
CURY locked-nucleid acid (LNA) miRNA ISH buffer
(Qiagen, 339450). Digoxigenin labeled miRCURY LNA
probes (HSA-MIR-10B-5P Cat No. 339111YD00610135-
BCE, SCRAMBLE-MIR Cat No. 339111YD00699004-
BCE, miRCURY LNA U6 Cat No. 339111YD00699002-
BCE, Qiagen) were diluted in hybridiziation buffer (cells:
80 nM, tissue sections: 100 nM) after a denaturation step
at 90 °C and incubated on cells for 30min (60min tissue
sections) at 54 °C (52 °C tissue sections). After probe
hybridization increasingly stringent washing steps were
applied in saline-sodium citrate (SSC) buffer (Sigma, SSC
20x buffer concentrate S6639-1 L) at various concentra-
tions and temperatures. Tris based (100mM) buffer was
supplemented with 3% (v/v) FCS, 1% (w/v) hyridization
blocking reagent (Roche, 339450), 0.3% (v/v) Triton-X100
and NaCl (150mM). Anti-DIG Fabs (Roche,
11207741910), Alexa Fluor® 647 Mouse Anti-Human
Cytokeratin 14, 15, 16 and 19 Clone KA4 (Supplementary
Table S2 in Additional File 1) and DAPI were used for
visualization and co-staining of cells and tissue sections,
respectively. Slides were mounted using Prolong Gold
Antifade mounting medium (Sigma, P36930).
Imaging was performed on a LSM800 Airyscan confocal
microscope (Zeiss). Analysis was conducted in ImageJ
(v1.52i) and CellProfiler (v3.0.0) with all steps documented
in scripts and workflow files, available upon request. Cel-
lular boundaries were detected based on respective fluor-
escence signals and signal intensities were integrated at
single cell resolution. To confine the analysis to cytoplas-
mic signals, nuclei were demarked via DAPI staining and
co-localizing fluorescence signals were subtracted from
total fluorescence. Downstream statistical analysis was
performed in statistical software R (v3.5.1).
Histological analysis of tissue sections and
immunofluorescence microscopy
cSCC samples from patients undergoing tumor resection
were FFPE processed [25]. Hematoxilin & eosin (H&E)
stainings were performed for histological assessment by
a dermato-histopathologist (Department of Dermatol-
ogy, University Hospital Salzburg).
For immunohistochemistry (IHC), sections were incu-
bated at 58 °C for 1 h, and subsequently deparaffinized
three times in Roti-Histol (Roth, 6640) at room
temperature (RT). Next, sections were washed in decreas-
ing alcohol concentrations (3 × 100% EtOH, 2 × 90% iso-
propanol, 1 × 70% isopropanol, 1 × dH2O). Heat-induced
antigen retrieval was performed in citrate buffer pH 6.0.
Upon blocking with 5% bovine serum albumin (BSA,
Sigma, A3294) in PBS, first antibodies were diluted in 2%
BSA/PBS. For all antibodies, a respective second-step con-
trol was included. Secondary antibodies were used at a 1:
500 dilution (Supplementary Table S2 in Additional File 1).
DAPI was used for nuclear staining (Sigma Aldrich,
D9542). The same protocol was used for cultured cells.
There, about 3 × 104 cells were seeded into 1 cm2 chamber
slides. After 24 h (hrs) cells were fixed for 10min in 4% for-
maldehyde in PBS, washed once with PBS and blocked at
room temperature for 1 hour with 2% BSA in PBS. Imaging
was performed on a Zeiss LSM710 confocal microscope.
Cloning of MIR10B and stable transduction
For stable expression of miR-10b in E6/E7 immortalized
RDEB-KCs, the human MIR10B gene was cloned into
the pMX-IRES-Blasticidin vector (Cell Biolabs Inc.,
RTV-016), downstream of the constitutive Pol-III U6
promoter. Primer sequences are given in Supplementary
Table S3 in Additional File 1. All constructs were ana-
lyzed using Sanger sequencing before viral packaging.
Viral particle production using pMX_U6_miR10b was
done as described previously [26]. Expression and mat-
uration of miR-10b was confirmed by TaqMan qPCR
(Supplementary Fig. S1C-E in Additional File 1).
CRISPR-mediated knock-out of MIR10B
Two single guide (g) RNAs, flanking the MIR10B stem
loop region on chromosome 2, were rationally designed
and selected to specifically knock-out MIR10B. Single
gRNAs were synthesized and purified using the Precision
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gRNA Synthesis Kit according to the manufacturer’s in-
structions (Thermo Fisher Scientific, A29377). Two pri-
mer sets were used for gRNA synthesis (Supplementary
Table S3 in Additional File 1). Recombinant spCas9 was
purchased from Polyplus-transfection (Polyplus-transfec-
tion). Ribonucleoproteins (RNPs) were complexed in a 4:
1 ratio (3 μg spCas9 and 750 ng sgRNAs; 375 ng each
sgRNA) for 10 min at RT and delivered into RDEB-
SCC1 keratinocytes by nucleofection using the Neon
Transfection System 10 μL Kit (Thermo Fisher Scientific,
MPK10025). SCC cells were trypsinized and washed with
PBS, and 3 × 105 keratinocytes were resuspended in
12 μL Resuspension Buffer R per reaction. RNP com-
plexes were added to each sample and electroporated
into SCC cells (~ 2.5 × 105 cells) under the following
conditions: 1400 V, 20 ms, 2 pulses. After electropor-
ation, cells were seeded into 6-well plates containing
pre-warmed antibiotic-free CnT-Prime Epithelium Cul-
ture Medium (CELLnTEC).
Migration assay
Cell motility assays were performed using 2-well silicone
inserts with a defined cell-free gap, suitable for wound
healing / migration assays (IBIDI, 80241). 7 × 104 cells in
70 μL CnT-Prime medium were seeded per well.
Twenty-four h post seeding silicone inserts were re-
moved and migration of cells was monitored at different
time points by measuring cell confluence in a pre-
defined, constant area including the gap using a Spark®
10M multimode microplate reader imaging module
(Tecan). Gap-area was calculated using ImageJ (v1.52i).
In parallel to every migration assay, proliferation of each
cell type was measured in 24-well plates, to exclude
varying proliferation rates as confounding factor.
Generation of 3D tumor spheroids
Spheroids were grown as floating spheres in AggreWell™
400Ex Plates (Stem-cell Technologies, 34425) according
to the manufacturer’s recommendations. 2.35 × 105 cells
/ well were seeded in CnT-prime medium supplemented
with 1.2 mM CaCl2. Spheroids were grown for 96 h. Ag-
gregates were transferred into a 24-well plate for im-
aging on a Spark®10M multimode microplate-reader
with integrated imaging module (Tecan). For live/dead
stainings, aggregates were purified using Corning® Co-
star® Spin-X® Centrifuge tube filters (0.22 μm) (Corning,
CLS8161-100EA). Viability was tested via live/dead via-
bility/cytotoxicity kit (Thermo Fisher, L3224). Imaging
was performed on a Zeiss LSM710 confocal microscope.
TECAN whole well images were processed in ImageJ
(v1.52i) software. All image processing was documented
in ImageJ macros and downstream statistical analysis in
R (v3.5.1) scripts, which are available upon request.
For outgrowth experiments, spheroids were transferred
to standard 24-well plates and incubated at 37 °C in a
humidified incubator using CnT-Prime Epithelium Cul-
ture Medium. Cellular outgrowth was imaged 24 h post
transfer.
Semi-quantitative real-time PCR
SqRT-PCR was performed using the GoTaq® qPCR
Master Mix (Promega, TM318), according to the
manufacturer’s protocol. Glycerinaldehyd-3-phosphat-
dehydrogenase (GAPDH) and tubulin alpha 1 (TUBA1)
were used as reference genes. For primers see Supple-
mentary Table S3 in Additional File 1. Data collection
was performed on a CFX96 (BioRad) instrument. Rela-
tive target gene expression quantities and significance
levels (unpaired two-sided t-test) were calculated using
the ΔΔCq method. All reactions were performed in
technical duplicates, and performed in at least three in-
dependent experiments.
Western blot analysis
Protein extracts were generated from ~ 5 × 105 cells at a
confluency of 80%, dissolved and homogenized in RIPA buf-
fer (Santa Cruz, sc-24948) supplemented with 5% ß-Mer-
captoethanol (ß-ME). Proteins were separated on a 4–15%
bis-tris gel (Invitrogen, Nupage, NP0323) in MOPS buffer
and blotted onto a 0.45 μm nitrocellulose membrane (Amer-
sham Biosciences, Hybond-ECL, Merck, GERPN303D).
Ponceau Red staining was performed for total protein ana-
lysis of ChemiDoc (BioRad) images in ImageLab software
(BioRad, v5.2.1). Membranes were blocked using 5% milk
powder in TBS / 0.1% Tween20 (Merck, 655205-250ML).
All antibodies are listed in Supplementary Table S2 in Add-
itional File 1. Membranes were washed five times using TBS
/ 0.1% Tween-20. HRP activity was visualized using the
Amersham ECL Select Western blot detection reagent
(Amersham Biosciences, RPN2235), and the ChemiDoc
system (BioRad). Specificity of the DIAPH2 antibody was
confirmed in DIAPH2 knock-out cells. Dosimetric semi-
quantitative analysis was performed in either ImageLab
(BioRad, v5.2.1) or ImageJ (v 1.52i).
MiR-10b mimic transfections
Primary healthy control keratinocytes (HC-KC) were
transiently transfected using Xfect transfection reagent
(TaKaRa Bio, 631450/631317) with 50 nM miR-10b-5p
mimic / ~ 105 cells (Thermo Fisher, miRVana, 4464066)
or scrambled control (Merck, HMC0002) according to
manufacturer’s protocol. Cells were lysed 72 h post-
transfection in RIPA buffer (Santa Cruz, sc-24948) sup-
plemented with 5% ß-ME for subsequent Western blot
analysis.
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Results
MiRNome profiling identifies up-regulation of miR-10b in
RDEB-cSCC
In order to identify differences in the miRNA expression
profile between cultured primary keratinocytes (KC) and
cSCC cells (Supplementary Information and Supplemen-
tary Table S1 in Additional File 1), we conducted an
Affymetrix GeneChip™ miRNA 4.1 expression analysis.
Out of 2578 analyzed mature miRNAs unique to human,
50 miRNAs were found to be significantly (p-value ≤0.05
and false discovery rate (FDR) ≤ 0.2) ≥ 2-fold up- or
down-regulated in RDEB-cSCCs (n = 4) compared to
RDEB-KC (n = 6), and 56 in HC-cSCCs (n = 3) com-
pared to healthy control (HC)-KCs (n = 5, Supplemen-
tary Fig. S1A, Supplementary Tables S4 and S5 in
Additional File 1). When analyzing miRTarbase v6.1 pre-
dicted targets of the deregulated (≥ 2-fold, p-value ≤0.05
and FDR ≤ 0.2) miRNome, various cancer-related Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways,
e.g. signaling pathways regulating pluripotency of stem
cells, appeared significantly enriched (Supplementary
Fig. S1B, Additional File 1).
To assess the ability of the miRNA expression profile
to distinguish cSCCs from other experimental groups we
performed principal component analysis (PCA). Annota-
tion of the samples within the distinct clusters showed a
clear separation of experimental groups (Fig. 1a). Even
though the miR-10 family was found to be overall upreg-
ulated in cSCCs, in-depth analysis of major contributors
driving the unsupervised cluster separation highlighted
miR-10b, which was 2.2-fold (p < 0.05) upregulated in
RDEB-cSCCs and 2.2-fold (p < 0.05) in HC-cSCCs, re-
spectively, compared to their non-malignant controls
(Fig. 1b, c). Despite the fact that miR-10a appeared to be
the most deregulated miRNA in RDEB-cSCCs in micro-
array analysis, but not in subsequent qPCR, we assume
that high microarray scores most likely derived from a
certain hybridization error rate, as miRs-10a and -10b
differ in only one nucleotide (Fig. 1e, Supplementary Fig.
S1C-E, Additional File 1). In addition, consistently in-
creased miR-10b (on average 9-fold), but not miR-10a
levels in RDEB-cSCC were found in previously generated
RNA sequencing (RNA-seq) data, where immortalized
HC-KC lines were used as controls (Supplementary Fig.
S1F,G, Additional File 1). Thus, we focused on miR-10b
and dropped miR-10a from further experiments. Pre-
dicted miR-10b targets were further tested for gene set
enrichment in cancer hallmarks (Molecular Signature
Database v6.2), and showed significant association with
metastatic processes like epithelial to mesenchymal tran-
sition (EMT) (Fig. 1d).
In summary, the results of a microarray based miRNA
expression profiling revealed a deregulated miRNome
able to distinguish cSCC from keratinocytes. In
particular, miR-10b was significantly upregulated in cul-
tured cSCC.
Expression of miR-10b in cSCC tissues
In order to localize and further substantiate upregulation
of miR-10b expression in tissue, we optimized a com-
bined IHC-ISH protocol using LNA probes.
When tissue specific expression was examined in FFPE-
sections of archival skin and tumor biopsies, miR-10b was
found to be upregulated in cSCC, particularly in RDEB-
cSCCs. Expression was predominantly co-localized to
keratin-positive cells (Fig. 1f, Supplementary Fig. S2A-C,
Additional File 1), tumor vasculature and lymphocytes (Sup-
plementary Fig. S2D in Additional File 1). Notably, both vas-
culature and hemopoietic cells have previously been shown
to express miR-10b in a tumor context [15, 18, 27–29]. Fur-
ther analysis of RDEB-tissues showed a strong expres-
sion of transcription factor TWIST1, a known
upstream driver of miR-10b-mediated tumor malig-
nancy. In addition, TWIST1 was also found to be up-
regulated in cultured SCC cells in IF and Western blot
analysis (Supplementary Fig. S2E,F, Additional File 1)
[14, 30]. Single cells in an RDEB-cSCC lymphnode
metastasis (RDEB-SCC LM) expressed high levels of
miR-10b. Less pronounced miR-10b abundance was ob-
served in HC-cSCC (Fig. 1f).
To investigate whether miR-10b expression was corre-
lated to differentiation, cells were incubated in the pres-
ence of calcium and serum to induce differentiation, and
respective marker gene expression was analyzed in paral-
lel to miR-10b expression levels. However, no correl-
ation between differentiation and miR-10b expression
was observed (data not shown).
Taken together, results of the IHC-ISH show high
abundance of miR-10b in cSCC tumor biopsies.
MiR-10b confers anchorage-independent aggregation
capabilities to keratinocytes and attenuates mobility
Metastasis requires the dissemination and successful es-
tablishment of clones with tumor-initiating potential at
distant niches [31]. In order to investigate the biological
role of miR-10b, we analyzed its expression levels in ex-
perimental cell lines using IHC-ISH, in parallel to 3D
tumor spheroid formation assays. As the cytoplasm is
considered as the site of miRNA maturation and action,
fluorescence intensity, excluding the nuclear region, was
assessed at a single cell resolution. MiR-10b was con-
firmed to be highly expressed in RDEB-cSCC cell lines
using ISH probes specific for mature miR-10b, and in
two out of three HC-cSCC cultures, as compared to pri-
mary HC-KCs (Fig. 2a, b, Supplementary Fig. S3,4 in
Additional File 1).
Next, we performed aggregate formation assays to ex-
plore the capacity of experimental cell lines to form
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anchorage independent spheroids [32]. All three RDEB-
cSCCs, and two out of three HC-cSCCs formed stable
aggregates (Fig. 2c, d). RDEB-KCs, which were used
as surrogate for functional experiments in all down-
stream experiments, stably overexpressing miR-10b
(RDEB-KCmiR-10b), as well as HC-KCmiR-10b, phe-
nocopied RDEB-cSCCs in the formation of stable
spheroids (Fig. 2e). Expression and maturation of
miR-10b, driven by the constitutive Pol-III U6 pro-
moter, was confirmed by qPCR (Supplementary Fig.
S5A, Additional File 1). In addition, we found that
KCmiR-10b were significantly smaller than their paren-
tal cells (p-valueRDEB-KC = 0.002; p-valueHC-KC < 0.001;
Supplementary Fig. S6A in Additional File 1). Like in
RDEB-cSCC derived aggregates, viable cells were
found predominantly in the outer spheroid layers of
KCmiR-10b spheres (Supplementary Fig. S5I in Add-
itional File 1). Parental RDEB- and HC-KCs formed
fewer and rather loose aggregates, which did not
withstand mild pipetting (Fig. 2e).
Fig. 1 miR-10b is upregulated in RDEB-cSCC. a Unsupervised clustering via PCA on miRNA expression levels clearly separated RDEB-cSCC (n = 4)
and HC-cSCC (n = 3) samples from RDEB-KC (n = 6) and HC-KC (n = 5). Target analysis of miR-10b, which was significantly (p≤ 0.05) up-regulated
(≥ 2-fold) in both, b HC-cSCCs and (c) RDEB-cSCCs, indicated an enrichment of pathways related to aggressive tumor phenotypes like epithelial-
to-mesenchymal transition (EMT) (d). e TaqMan qPCR (n = 3 ind. repl., mean ± SEM, *p < 0.05, n.s. non-significant, unpaired t-test), as well as (f)
fluorescence-based in situ hybridization (FISH) with DIG labelled miR-10b probes (green) on FFPE tissues sections of confirmed (H&E staining, top
row) carcinomas also showed miR-10b dysregulation. White dashed line: tumor boundaries marked by pan-keratin staining (red). Scale bars:
100 μm (white), 500 μm (black). Sample codes (e) from left to right HC-KC: 1090KC, SKC013, SKC018; RDEB-KC: RDEB-55KC, RDEB-43KC, RDEB-29KC;
RDEB-cSCC: RDEB-SCC1, RDEB-SCC2, RDEB-SCC62; HC-cSCC: SCC13, WT18SCC, A431
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Fig. 2 Stable aggregate formation is associated with miR-10b expression. a DIG-labelled miR-10b-5p specific LNA probes (green) were used in an
in-situ hybridization protocol to quantify relative expression of miR-10b in cultured cells by FITC labeled anti-DIG-Fab immunofluorescence
imaging. All three tested RDEB-cSCCs and two out of three HC-cSCC cell lines demonstrated increased miR-10b signals compared to primary HC-
KCs. b To quantify the miR-10b expression at single cell resolution, cytoplasmic FITC signals of cells were cumulated and plotted as relative
fluorescence intensity per single cell on the x-axis. Graphic shows distribution density function of miR-10b intensity of all analyzed single cells per
sample. Respective negative- (scrambled) and positive- (U6) probes were used as controls (Supplementary Figs. S3 and S4 in Additional File 1). c
All RDEB-cSCC lines and two out of three HC-cSCC lines demonstrated stable aggregate formation 96 h post seeding (representative images of
aggregates). d Cross section of objects evaluated after transferring aggregates (n~ 7·103) into cell culture plates. Each dot represents one object. e
In addition, overexpression of miR-10b in KCs conferred spheroid formation capacities. Sample codes HC-KC: 1090KC, RDEB-KC: RDEB-57KC. Scale
bars: 50 μm (white), 100 μm (black)
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To further substantiate the link between miR-10b
overexpression and enhanced spheroid formation capaci-
ties, we knocked-out the MIR10B gene locus in RDEB-
cSCC cells (RDEB-SCC1MIR10B−/−) using the CRISPR/
Cas9 technology, and performed minimal dilution to po-
tentially obtain single clones, which was confirmed by
Sanger sequencing and qPCR on mature miR-10b ex-
pression levels (Supplementary Fig. S5J,K). In spheroid
formation assays we observed, that MIR10B knock-out
reduced the stability of aggregates and resulted in an in-
creased number of single cells and fragmented aggre-
gates (Fig. 3a-c). While PCR-mediated confirmation of
MIR10B knock-out showed only bands corresponding to
successful deletion, we found that over time single cells
that had escaped knock-out and subsequent clearance by
minimal dilution returned to dominance, independent of
a potential proliferative advantage (Fig. 3d, e). This was
observed in several clones and over several cultivation
passages, pointing towards a potential survival advantage
of cells expressing miR-10b. When subjecting these
mixed cultures again to 3D-sphere formation assays,
their behavior resembled that of parental cells (Fig. 3a-
c). Another striking difference between parental and
MIR10B−/− cells was a reduced capacity to grow out of
tumor spheroids upon transfer to culture dishes. Spher-
oids adhered to dishes, and circularly outgrowing cells
became visible after 24 h in RDEB-SCC1 derived aggre-
gates, and to a much lower extent in RDEB-SCC1MIR10B
−/− cells. Again, this was reversed in mixed culture ex-
periments. A similar outgrowth pattern to RDEB-SCC1
was also observed in two out of three HC-cSCC derived
spheroid experiments (Fig. 3f).
As spheroid formation is a key attribute of cancer stem
cells (CSCs), and points towards the presence of cancer
stem cell-like properties, we analyzed accepted CSC
markers (CD44 / CD24) [33]. RDEB-cSCC cultures showed
an overall high expression of CD44, and varying levels of
CD24, including a CD44high / CD24−/low cell population. In
support of the hypothesis that miR-10b expression was as-
sociated with a CSC-like phenotype, overexpression of
miR-10b in KCs resulted in an overall ~ 2-fold enrichment
of CD44high / CD24−/low cells (Supplementary Fig. S6B,C in
Additional File 1).
We next examined whether the above observed proper-
ties were attributed to mobility-, or adhesion-associated
mechanisms [32]. Therefore, we conducted wound closure
assays using RDEB-KCmiR-10b and RDEB-SCC1MIR10B−/−
cells. We found that those cells expressing high levels of
miR-10b (i.e. RDEB-KCmiR-10b versus parental, parental ver-
sus RDEB-SCC1MIR10B−/−) demonstrated significantly im-
paired mobilization (time point 6 h: p < 0.01) (Fig. 4a, b). In
addition, when transiently transfecting SCC1MIR10B−/− with
a miR-10b mimic, as well as when using the mixed popula-
tion, gap closure was accelerated again (Fig. 4b, c). Notably,
HC-cSCCs showed faster gap closure than RDEB-cSCC
and primary HC-KCs, the latter two showing a similar mi-
gratory potential (Fig. 4d, e). When overexpressing miR-
10b in HC-KCs, no impact on migration was observed
(data not shown). The reason for the unexpected delay in
gap closure in RDEB-cSCCs remains speculative, but might
be due to prior exposure of RDEB-cells to pathological pro-
cesses like chronic inflammation, or the difference in matrix
composition, which is dramatically altered in RDEB patients
due to C7 absence [5–9]. Still, our results show that RDEB-
SCCs migrate more slowly that HC-cSCCs in general, and
miR-10b has an impact on mobility. No impact on prolifer-
ation was observed in the presence or absence of miR-10b.
Taken together, our data suggest for the first time that
CSC-like properties can be conferred by miR-10b, a here-
tofore unknown aspect of miR-10b driven malignancy in
cSCCs, and indicates an impact on motility in RDEB.
DIAPH2 is deregulated in RDEB-cSCC and predicted to be
a target of miR-10b
To analyze the impact of miR-10b on its targetome, we
first screened the scientific literature in an automated
text-mining approach for miR-10b in cancer, which
highlighted the previously reported, direct miR-10b tar-
get transcription factor HOXD10 [14], (Supplementary
Fig. S7A in Additional File 1). We observed significantly
reduced levels of HOXD10 protein in three RDEB-cSCC
cell lines compared to HC-KC, and also in an RDEB-
cSCC tissue section, compared to HC- and RDEB-skin
[34], (Supplementary Fig. S7B-D in Additional File 1).
To next identify novel downstream targets of miR-10b,
data driven miR-10b target identification was implemented
based on transcriptome data generated from miRNA
microarray-matched RDEB-cSCC and RDEB-KC samples.
Of the 576 differentially expressed genes identified (≥ 2-fold
↓↑) in RDEB-cSCCs, 114 were reported in merged reposi-
tory data (n = 3923) of validated miR-10 targets (miRTar-
base v6.1), as well as computationally predicted targets by
seed sequence and evolutionary conservation (TargetScan
v7.2). Dysregulated putative miR-10 interaction partners
were further prioritized by strength of their inverse correl-
ation of expression with miR-10 signal (Supplementary Fig.
S7E in Additional File 1). To nominate a disease relevant
miR-10b target, we analyzed publicly available survival data
from metastatic stage IV head and neck squamous cell car-
cinoma (HNSCC) (n = 86 patients, The Cancer Genome
Atlas / TCGA), as this cancer type was previously described
to have high genetic similarities to RDEB-cSCC [8]. The
top 20 candidate miR-10b targets with highest inverse cor-
relation were then used to stratify HNSCC patients (Sup-
plementary Fig. S8A and Supplementary Table S6 in
Additional File 1). We nominated diaphanous related for-
min 2 (DIAPH2) for further evaluation based on significant
differences in Kaplan Meier survival curves (p < 0.05, log-
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rank test, Fig. 5a), together with the fact that it was listed as
a putative target of miR-10b. Its potential disease-relevance
was substantiated by its recent association with colon carcin-
oma, and its potential role in actin-organization and micro-
tubule stabilization [35–37]. When re-analyzing normalized
RNA-seq data generated by Cho et al., retrieved from GEO-
repository (GSE111582), both, DIAPH2 and HOXD10,
showed lower expression in RDEB-cSCC versus RDEB-skin
tissue [8], (Supplementary Fig. S8B,C in Additional File 1).
To confirm DIAPH2 as a direct target of miR-10b, a
dual luciferase reporter assay was established by cloning
the 3’UTRs of DIAPH2 and HOXD10 as a control, re-
spectively, downstream of a firefly luciferase reporter
gene. Constructs were then co-transfected with a miR-
Fig. 3 Knock-out of MIR10B reduces aggregate sizes. a, b Knock-out of MIR10B in RDEB-cSCC shifts the distribution of cell aggregates towards an increased
number of single cells and aggregate fragments (indicated as small objects) in a size distribution analysis by cross-section of formed aggregates compared
to parental cells. This effect was reversed in a mixed culture of knock-out and parental cells. c The significant difference in size distribution was evaluated
by a Kolmogorov-Smirnoff (KS) test, where the null distribution of the KS test statistic was derived by Monte Carlo simulation upon random resampling
(parental, MIR10B−/− and mixed). d Extended culture period over several passages (> 10 passages) of MIR10B knock-out cells led to the prevailance of
residual miR-10b expressing cells, resulting in a mixed population of RDEB-SCC1MIR10B−/− and parental miR-10b expressing cells. In addition, upon short
trypsinization of a mixed population, we found that MIR10B knock-out cells detached earlier, whereas the remaining cells, showed an enrichment of those
cells still harboring the genomic MIR10B locus. (PCR on MIR10B locus in isolated genomic DNA). e Proliferation of miR-10b expressing parental cells showed
no difference to MIR10B knock-out cells or to a mixed population. Proliferation was assessed over 7 days. Mean ± SEM are given, n= 4 ind. repeats. f
Spheroids formed by miR-10b expressing parental RDEB-cSCC cells and a mixed population showed outgrowth of cells 24 h post aggregate transfer to cell
culture plates. This phenomenon was much less pronounced in MIR10B knock-out cells. HC-cSCC (e.g. SCC13) also presented with outgrowth from
spheroids within 24 h post transfer similar to RDEB-cSCC (representative images from two independent repeats)
Wimmer et al. Cell Communication and Signaling           (2020) 18:61 Page 9 of 15
10b mimic into HC-KCs, which express only low levels
of endogenous miR-10b. In the presence of miR-10b
mimic, luciferase signal was significantly reduced (p-
valueDIAPH2 = 0.015; p-valueHOXD10 < 0.01) compared to
scrambled (SCR) control (Supplementary Fig. S7F,G in
Additional File 1).
We next assessed DIAPH2 expression in cultured cSCCs
and control KC. Both, at the mRNA and the protein level,
DIAPH2 was downregulated in RDEB-cSCC cells, with no
significant difference between HC- and RDEB-KC (Fig. 5b,
d, Supplementary Fig. S7I in Additional File 1). In addition,
DIAPH2 was also slightly downregulated in RDEB-
KCmiR-10b, as shown by sqRT-PCR (Supplementary Fig. S5B
in Additional File 1). In HC-cSCCs, DIAPH2 expression
levels were not as consistently reduced as in RDEB-cSCC
and differed significantly between cell lines (Fig. 5c, d).
Fig. 4 Gap closure is affected by miR-10b expression. a Stable overexpression of miR-10b in an E6/E7 immortalized RDEB keratinocyte line (RDEB-
KCmiR-10b) prolonged the time to gap closure compared to parental cells (RDEB-KCE6/E7; n≥ 8 ind. experiments). b Knock-out of MIR10B in RDEB-
SCC1 (RDEB-SCC1MIR10B−/−) enhanced gap closure compared to parental cells (RDEB-SCC1), whereas a mixed culture of miR-10b expressing cells
with RDEB-SCC1MIR10B−/− resembled parental results (n≥ 3 ind. experiments). c Transient transfection of a miR-10b mimic into RDEB-SCC1MIR10B−/−
decelerated gap closure in knock-out cells compared to scrambled control (two ind. experiments with n = 4 technical replicates each, one
representative run shown). d Gap closure of three HC-cSCC and (e) three RDEB-SCC cell lines compared to primary HC-KC (1090KC; n = 3
independent experiments). Data represented by mean ± SEM, *p < 0.05, n.s. non significant, unpaired t-test. Representative images are shown for
either time points until gap closure. Red line indicates six hour time point in each experiment
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Fig. 5 (See legend on next page.)
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Notably, following transient transfection of HC-KCs with
miR-10b mimic, DIAPH2 protein levels were found to be
significantly reduced (~ 29%, p = 0.05) compared to SCR
control (Supplementary Fig. S7H in Additional File 1), and
it recurred in RDEB-SCC1MIR10B−/− as investigated by
Western blot analysis and immunofluorescence microscopy
(Fig. 5e). DIAPH2 downregulation was also evident in
RDEB-cSCC tissue sections (Fig. 5f). Taken together,
DIAPH2 appeared as target of miR-10b in RDEB-cSCCs,
although inconsistent results in HC-cSCCs indicate further,
miR-10b independent regulatory mechnisms.
To examine if a loss of DIAPH2 in keratinocytes pheno-
copies the observed migratory behavior in RDEB-KCmiR-10,
we knocked out DIAPH2 in immortalized HC-KCs using
the CRISPR/Cas9 technology (HC-KCDIAPH2−/−). Clones
were generated by minimal dilution and knock-out was
confirmed by Sanger sequencing and Western blot analysis
(Supplementary Fig. S5C,D in Additional File 1). While
proliferation was not altered, DIAPH2−/− cells showed
significantly impaired motility over parental HC-KCs (Sup-
plementary Fig. S5E,F). In addition, when analyzing HC-
KCDIAPH2−/− in a 3D-sphere formation assay, a trend
towards enhanced aggregation was observed, with a distri-
bution of spheroid size similar to cSCCs (Supplementary
Fig. S5G,H). Overall, the functional impact of DIAPH2
knock-out resembled our observations in RDEB-KCmiR-10
and RDEB-SCC1MIR10B−/−.
Our work taken as a whole has demonstrated that
miR-10b is overexpressed in cSCC cells and tissues, and
that miR-10b confers tumor-associated properties to
KCs. In addition, deregulation of DIAPH2, a novel puta-
tive miR-10b downstream target, might represent a con-
tributing factor in cSCC malignancy.
Discussion
Various factors are presumed to contribute to the devel-
opment of cSCCs in RDEB patients, however, the role of
miRNAs in the context of RDEB has not yet been ad-
dressed. In this study, our aim was to identify miRNAs in-
volved in the development or progression of particularly
aggressive cSCCs in general, and in RDEB-cSCCs in
particular, by profiling the miRNome of human cSCCs, as
well as keratinocytes. As miR-10b was found to be signifi-
cantly upregulated in cSCCs in vitro and in situ, we next
examined its functional impact on cultured human kerati-
nocytes. We conducted 3D-sphere formation assays using
keratinocytes overexpressing miR-10b, and cSCC cells
where the MIR10B gene locus had been knocked-out.
While overexpression of miR-10b improved the ability of
cells to form stable 3D-spheroids, similar to those derived
from aggressive cSCC cells, knock-out significantly reduced
spheroid stability. As spheroid formation is a capacity for
anchorage-independent survival, generally attributed to
cells with the potential to initiate tumor growth, such as
CSCs, this shift towards stemness upon miR-10b overex-
pression in RDEB-keratinocytes was confirmed through an
enrichment of CD44high/CD24−/low cells [38]. Unfortu-
nately, tumor initiation experiments in immunodeficient
mice did not result in the engraftment of cells, or the devel-
opment of a tumor, likely due to their overall non-
malignant background of RDEB keratinocytes. Notably, not
all RDEB-cSCC lines are able to successfully engraft in im-
munodeficient mice, highlighting that other factors, such as
a supportive microenvironment, are required. However, the
observation that miR-10b is overexpressed and may have a
functional role in mediating stemness highlights a novel as-
pect of miR-10b function in cSCC, that is separate from its
well demonstrated role in EMT.
As increased motility is considered as a hallmark of tumor
cells undergoing EMT, we were interested in the effect of
miR-10b on KCs and cSCCs. When next performing migra-
tion assays using miR-10b overexpressing and knock-out
cells, we found an attenuated gap closure in the presence of
miR-10b, which we also observed when reintroducing miR-
10b in knock-out cells. Also RDEB-cSCC cell lines showed
no enhanced gap closure compared to keratinocytes, which
was contrary to our expectation that cancer cells migrate fas-
ter than non-malignant controls. However, opposed to
RDEB-cSCCs, HC-cSCCs showed an increased migratory
behavior over control cells. This leads to the assumption,
that while there are clear similarities between HC-cSCCs
and RDEB-cSCC in miR-10b expression levels and spheroid
(See figure on previous page.)
Fig. 5 DIAPH2 is a direct downstream target of miR-10b in RDEB-cSCC. a Kaplan-Meier curves of the metastatic HNSCC (TCGA RNAseq and clinical
data filtered for stage IV, N3). Data show significant (p = 0.024, log-rank test) impact of DIAPH2 expression (75% quantile is considered for
stratification between high and mid/low expression) on mean survival time (mst) mst DIAPH2
high = 2166 vs. mst DIAPH2
low = 806 days. b Overall
expression of DIAPH2 in cultured cells was significantly (p < 0.001) reduced in RDEB-cSCC (n = 3) compared to primary keratinocytes. No
significant difference was found between HC-KC and RDEB-KC in dosimetric Western blot analysis (data represented by mean ± standard
deviation of three independent experiments, unpaired t-test). c Significant (p = 0.045) lower DIAPH2 protein levels appeared in one out of three
HC-cSCC cell lines in relation to HC-KC (1090KC, mean ± SEM of three ind. experiments, unpaired t-test). d Immunofluorescence microscopy
confirmed reduced DIAPH2 levels in one out or three HC-cSCC and all three RDEB-cSCC cell lines (2 independent repeats). e Western blot analysis
shows recurrence of DIAPH2 expression in an RDEB-SCC1MIR10B−/− culture generated by serial dilution (data represented by mean ± SEM of three
ind. experiments, unpaired t-test). Immunofluorescence microscopy (two independent repeats) on RDEB-SCC1MIR10B−/− bulk culture compared to
parental RDEB-SCC1. f Immunostaining of DIAPH2 (green) and DAPI (blue) on HC-skin compared to HC-cSCC, RDEB-skin and RDEB-cSCC FFPE
tissue sections. Scale bars = 50 μm (c, e, f), and 1000 μm for H&E stainings
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formation capacities, and miR-10b confers tumor spheroid
formation capacities, there are also major differences be-
tween the two different types of cSCCs, that affect their mi-
gratory behavior. Obviously, the absence of the ECM
protein type-VII collagen is a major contributor to tumor
formation in RDEB [6–9]. Loss of COL7A1 leads to im-
paired re-epithelialization through perturbation of
laminin-332 organization and abrogation of strictly polar-
ized expression of integrin α6β4 in basal keratinocytes,
which together finally impacts guided keratinocyte migra-
tion – an essential step in wound closure [39].
Overall, it has been repeatedly reported that EMT is ne-
cessary for cells to disseminate from the primary tumor
and become circulating tumor cells (CTCs), complemen-
tary models of metastasis exist [31, 40]. One pre-requisite
for CTCs is to maintain their ability to revert from the mes-
enchymal to the epithelial phenotype (MET). Another is
based on the concept of “collective” or “cohort” migration.
In this case it is assumed that epithelial-like and
mesenchymal-like cancer cells circulate in clusters and act
cooperatively to promote metastatic growth, without the
need to undergo complete EMT/MET [41]. Ultimately, a
key event during metastasis is that cells with a tumor-
initiating capacity reach and establish at distant sites to
form new colonies, which requires cell adhesion [31]. We
hypothesize that the increased adhesive potential and
sphere formation capacity following overexpression of miR-
10b, might not only increase cell survival in the circulation,
but also facilitate extravasation at new sites, and explains in
part the propensity of aggressive cSCCs to metastasize [42].
Alternatively, changes in the actin- and / or microtubule
cytoskeleton, which impact cell motility [43], could ac-
count for slower wound closure rates and increased sticki-
ness in RDEB skin. In this context, the putative miR-10b
target DIAPH2, a protein belonging to the formin hom-
ology family, which has previously been associated with
actin filament assembly, microtubule formation and
vesicle shuttling, might be a modulator of cell motility in
RDEB-cSCCs [44, 45]. In this study, DIAPH2 was pre-
dicted to be a target of miR-10b in silico, which we add-
itionally confirmed using a luciferase-reporter assays.
Notably, while miR-10b overexpression did not result in
efficient knock-down of DIAPH2 in RDEB-KCs, a signifi-
cant downregulation of DIAPH2 was observed in RDEB-
cSCC expressing high endogenous levels of miR-10b, and
re-expression of DIAPH2 was demonstrated upon
MIR10B knock-out in RDEB-cSCC cells. This indicates
potential alternative pathways of DIAPH2 regulation in
non-malignant cells. Nonetheless, CRISPR-mediated
knock-out of DIAPH2 resulted in functional outcomes
similar to those observed in miR-10b overexpressing kera-
tinocytes, including attenuated migration and an en-
hanced capacity to form 3D-spheroids. While only limited
information on DIAPH2 is available, DIAPH3, a closely
related family member with 57% sequence homology and
several common protein binding domains, does promote
cell growth and metastasis in hepatocellular carcinoma
[46]. Supporting our findings, knock-down of DIAPH3 re-
sults in reduced migration [47]. DIAPH2 is predicted to
interact with small RHO-GTPases, which are implicated
in motility, and frequently downregulated in different
types of SCCs [48, 49]. In line with this, our microarray
data also indicate a slight downregulation of RHOC and
RHOD in RDEB-cSCC. Considering this, a similar func-
tion of DIAPH2 in the context of cSCCs is likely but needs
to be further explored.
In summary, overexpression of miR-10b impacts cellular
processes at various levels. The extent of the response is
dependent on the cellular context, the presence of certain
target mRNAs, and/or mutations in those target mRNAs
[50]. In the context of cSCCs, we showed that miR-10b
confers anchorage-independent spheroid formation cap-
acities, indicating a phenotypic shift towards stem cell-like
properties. We hypothesize, that these findings might be
involved in tumor progression at the stages of extravasa-
tion and metastatic colonization, processes in which both
anchorage-free survival, as well as cell surface interaction,
are important pre-requisites.
Conclusion
Overall, our results demonstrate for the first time the up-
regulation of miR-10b in aggressive cSCCs. While new,
these findings provide a potential so far unreported pro-
metastatic function of miR-10b, as this miRNA confers
cancer stem cell-like properties, like increased adhesion,
spheroid formation capacities and associated cellular out-
growth, which are essential characteristics associated with
metastasis. However, also differences between RDEB-
cSCC and HC-cSCC cells were observed, affecting their
migratory potential, which point towards a potential im-
pact of the respective genetic background. The results of
this study provide an exciting new opportunity for the de-
velopment of future therapies to treat this rare and debili-
tating disease. In addition, miR-10b expression in cSCC
might hold potential as a biomarker for early diagnosis
and / or therapy monitoring in the context of aggressive
cSCC, as these tumors often escape early detection due to
their predominant emergence within chronic wounds.
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